MyoKardia (MYOK) Stock Price, News & Analysis

Company Overview

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.

Key Stats

• Today's Range: $224.91 to $224.91
• 50-Day Range: $222.81 to $224.91
• 52-Week Range: $42.65 to $225.00
• Volume: N/A
• Average Volume: 752,969 shs
• Market Capitalization: $11.99 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MYOK Stock Analysis - Frequently Asked Questions

How were MyoKardia's earnings last quarter?

MyoKardia, Inc. (NASDAQ:MYOK) announced its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.16.

What other stocks do shareholders of MyoKardia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MyoKardia investors own include NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Micron Technology (MU) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/05/2020
• Today: 12/22/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MYOK
• CUSIP: N/A
• CIK: 1552451
• Web: www.myokardia.com
• Phone: 650-741-0900
• Fax: N/A
• Employees: 318
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-276,210,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.99%
• Return on Assets: -42.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 21.03
• Quick Ratio: 21.03

Sales & Book Value

• Annual Sales: $33.56 million
• Price / Sales: 357.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.79 per share
• Price / Book: 25.59

Miscellaneous

• Outstanding Shares: 53,323,000
• Free Float: N/A
• Market Cap: $11.99 billion
• Optionable: Optionable
• Beta: 1.84